ID

23356

Description

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00360334

Link

https://clinicaltrials.gov/show/NCT00360334

Keywords

Versions (1)
  1. 7/3/17 7/3/17 -
Uploaded on

July 3, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes NCT00360334

English

Eligibility Type 2 Diabetes NCT00360334

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with type 2 diabetes
Description

Diabetes Mellitus, Non-Insulin-Dependent

Data type

boolean

Alias
UMLS CUI [1]
C0011860
currently being treated with the following: dual or triple oral therapy - on a stable combination and dose for at least 3 months.
Description

Therapeutic procedure Oral Duplicate | Therapeutic procedure Oral Triplicate | Combined Modality Therapy Dose Stable

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C0205173
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205174
UMLS CUI [3,1]
C0009429
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
hba1c between 7.5% and 10.0%.
Description

Glycosylated hemoglobin A

Data type

boolean

Alias
UMLS CUI [1]
C0019018
bmi >27.
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.
Description

Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation

Data type

boolean

Alias
UMLS CUI [1,1]
C0744425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C0205191
UMLS CUI [2]
C0017712
UMLS CUI [3,1]
C0017710
UMLS CUI [3,2]
C0205535
have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.
Description

Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0184661
UMLS CUI [3]
C0087111
UMLS CUI [4]
C0543467
UMLS CUI [5]
C0013230
treatment with the following medications: *insulin as outpatient therapy within last 3 months; *meglitinides, or acarbose within the last 3 months; *regular use of any drugs that directly affect gastrointestinal motility; *any previous (study) therapy with exenatide or glucagon-like peptide-1 (glp-1) analogue; *anti-obesity agent use within the last 3 months.
Description

Insulin | Meglitinide | Acarbose | Pharmaceutical Preparations Affecting Gastrointestinal Motility | exenatide | Glucagon-Like Peptide 1 Analogue | Anti-Obesity Agents

Data type

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2]
C0065880
UMLS CUI [3]
C0050393
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C0392760
UMLS CUI [4,3]
C0017184
UMLS CUI [5]
C0167117
UMLS CUI [6,1]
C0061355
UMLS CUI [6,2]
C0243071
UMLS CUI [7]
C0376607
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Description

Drugs, Non-Prescription

Data type

boolean

Alias
UMLS CUI [1]
C0013231
Back to the top of the page

Similar models

Eligibility Type 2 Diabetes NCT00360334

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Therapeutic procedure Oral Duplicate | Therapeutic procedure Oral Triplicate | Combined Modality Therapy Dose Stable
Item
currently being treated with the following: dual or triple oral therapy - on a stable combination and dose for at least 3 months.
boolean
C0087111 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0205173 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205174 (UMLS CUI [2,3])
C0009429 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Glycosylated hemoglobin A
Item
hba1c between 7.5% and 10.0%.
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
bmi >27.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation
Item
receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.
boolean
C0744425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0017712 (UMLS CUI [2])
C0017710 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs
Item
have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.
boolean
C2348568 (UMLS CUI [1])
C0184661 (UMLS CUI [2])
C0087111 (UMLS CUI [3])
C0543467 (UMLS CUI [4])
C0013230 (UMLS CUI [5])
Insulin | Meglitinide | Acarbose | Pharmaceutical Preparations Affecting Gastrointestinal Motility | exenatide | Glucagon-Like Peptide 1 Analogue | Anti-Obesity Agents
Item
treatment with the following medications: *insulin as outpatient therapy within last 3 months; *meglitinides, or acarbose within the last 3 months; *regular use of any drugs that directly affect gastrointestinal motility; *any previous (study) therapy with exenatide or glucagon-like peptide-1 (glp-1) analogue; *anti-obesity agent use within the last 3 months.
boolean
C0021641 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0050393 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0392760 (UMLS CUI [4,2])
C0017184 (UMLS CUI [4,3])
C0167117 (UMLS CUI [5])
C0061355 (UMLS CUI [6,1])
C0243071 (UMLS CUI [6,2])
C0376607 (UMLS CUI [7])
Drugs, Non-Prescription
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial